Nanatinostat
EBV-Related Leiomyosarcoma
Viracta Therapeutics, Inc.Small moleculePhase 1Active
C
37/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 22/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the EBV-Related Leiomyosarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tabelecleucel Pierre Fabre Medicament | Phase 2 | CCC |
Pembrolizumab Viracta Therapeutics, Inc. | Phase 1 | CC |
Valganciclovir Viracta Therapeutics, Inc. | Phase 1 | CC |
Same molecule, other indications
Nanatinostat is also rated in:
Epstein-Barr virus-associated lymphoproliferative disorderDormant
CCC
Indicative ·
49 / 100
View asset →Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderlyDormant
CC
Indicative ·
43 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →